So that’s an asset that we do anticipate hopefully getting into manufacturing sometime next year in 2024 to allow us to start to evaluate that asset. Also, probably later in the year, but we’ll provide updates regarding what the what we’re doing with that process program, what the potential partnerships, how we’re going to move that forward. We’ll provide some of, some more of those details later as the year, the year goes by in 2024 PDS0104, we have not yet made any additional progress with PDS0104. We’ve really concentrated on PDS0101, 0102, and 0103 at this point, as well as PDS01ADC.
Laura Suriel: And also, just one more question alongside the data presented for IMMUNOCERV, for your other investigator-initiated trial of PDS0101, this with the Mayo Clinics. Do you have any estimates as to when you might get data announced here?
Frank Bedu-Addo: No. So with the Mayo Clinic, starting with the Mayo Clinic, as you mentioned that’s another investigate-initiated trial, it’s evaluating the early stage HPV16 positive oral cancer in neoadjuvant setting. We have been informed, as I mentioned, by the PI, that they hope to present preliminary data at the scientific meeting in the first half of 2024. And so, we’ll keep you updated as we learn more as to what conference that would be and what the exact timing would be. But we are hopeful that we’ll see some data — we’ll see the first preliminary data from that trial, hopefully in the first half of 2024. And with IMMUNOCERV, the investigators are extremely encouraged with the data that they’ve seen today. Based on what we’ve been told by Dr. Klopp of MD Anderson who leads this trial, she’s actually planning on submitting interim results of the study for scientific publication, and particularly the recent circulating tumor HPV DNA outcomes reported at ASCO.
The previously reported tracking, and accumulation of multifunctional CDA T-cells in the tumors, and she also intends to update clinical response and survival data. So, we are hopeful that we’ll get an additional update on that trial in the near future.
Operator: Thank you. There are no other questions at this time. I’ll turn the floor back to Dr. Bedu-Addo for any final comments.
Frank Bedu-Addo: Thank you very much. So, thank you to all for participating in our third quarter earnings conference call today. The progress made this quarter has been truly exciting. We remain enthusiastic about what lies ahead for the rest of this quarter and into 2024. We have made significant strides towards our objective of developing groundbreaking therapies that transform cancer treatments. We are confident that our efforts will positively impact these patients with critical unmet medical needs leading to longer lives and improved quality of life. We appreciate your continued support and eagerly anticipate updating you on our accomplishments. Thank you very much again, and have a wonderful day.
Operator: Thank you. This concludes today’s conference call. You may disconnect your lines at this time. Thank you for your participation.
